BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35354796)

  • 1. TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells.
    Tantai J; Pan X; Chen Y; Shen Y; Ji C
    Cell Death Dis; 2022 Mar; 13(3):285. PubMed ID: 35354796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
    He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE4B promotes the development of lung adenocarcinoma by enhancing proliferation, migration and glycolysis via PP2A/AKT signaling.
    Wu S; Xie L; Cheng S; Fan Z; Sang H; Li Q
    Pathol Res Pract; 2022 Apr; 232():153762. PubMed ID: 35220170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tripartite Motif-Containing 46 Promotes Viability and Inhibits Apoptosis of Osteosarcoma Cells by Activating NF-B Signaling Through Ubiquitination of PPAR.
    Jiang W; Cai X; Xu T; Liu K; Yang D; Fan L; Li G; Yu X
    Oncol Res; 2020 Sep; 28(4):409-421. PubMed ID: 32295675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
    Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
    Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
    Zhang Y; Du H; Li Y; Yuan Y; Chen B; Sun S
    Cancer Sci; 2020 Feb; 111(2):637-646. PubMed ID: 31677335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
    Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M
    Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.
    Zhang S; Cao M; Yan S; Liu Y; Fan W; Cui Y; Tian F; Gu R; Cui Y; Zhan Y; Sun Y; Xing Y; Cai L; Song Y
    Int J Biol Sci; 2022; 18(7):2962-2979. PubMed ID: 35541909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CNTN-1 Enhances Chemoresistance in Human Lung Adenocarcinoma Through Induction of Epithelial-Mesenchymal Transition by Targeting the PI3K/Akt Pathway.
    Zhang R; Sun S; Ji F; Liu C; Lin H; Xie L; Yang H; Tang W; Zhou Y; Xu J; Li P
    Cell Physiol Biochem; 2017; 43(2):465-480. PubMed ID: 28934754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
    Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
    Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM46 contributes to high glucose-induced ferroptosis and cell growth inhibition in human retinal capillary endothelial cells by facilitating GPX4 ubiquitination.
    Zhang J; Qiu Q; Wang H; Chen C; Luo D
    Exp Cell Res; 2021 Oct; 407(2):112800. PubMed ID: 34487731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of CCT3 predicts poor prognosis and promotes cell proliferation via inhibition of ferroptosis and activation of AKT signaling in lung adenocarcinoma.
    Wang K; He J; Tu C; Xu H; Zhang X; Lv Y; Song C
    BMC Mol Cell Biol; 2022 Jun; 23(1):25. PubMed ID: 35773623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma.
    Chen Z; Hu Z; Sui Q; Huang Y; Zhao M; Li M; Liang J; Lu T; Zhan C; Lin Z; Sun F; Wang Q; Tan L
    Int J Biol Sci; 2022; 18(2):522-535. PubMed ID: 35002507
    [No Abstract]   [Full Text] [Related]  

  • 17. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP53 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through FKBP51-AKT1 signaling.
    Zhao X; Wu X; Wang H; Yu H; Wang J
    Mol Carcinog; 2020 Aug; 59(8):1000-1011. PubMed ID: 32511815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF149 confers cisplatin resistance in esophageal squamous cell carcinoma via destabilization of PHLPP2 and activating PI3K/AKT signalling.
    Zhu J; Tang J; Wu Y; Qiu X; Jin X; Zhang R
    Med Oncol; 2023 Sep; 40(10):290. PubMed ID: 37658961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma.
    Zhang K; Chen J; Li C; Yuan Y; Fang S; Liu W; Qian Y; Ma J; Chang L; Chen F; Yang Z; Gu W
    Cancer Lett; 2022 Feb; 526():142-154. PubMed ID: 34715254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.